We are owned and operated by folks in Tennessee
The FDA didnt do its due diligence, as is common in other drug litigation
Gastric Emptying Modulation Dual Pathway Effect Both components contribute to delayed gastric emptying through complementary mechanisms[5]: GLP3 delays gastric emptying primarily through GLP-1R and glucagon receptor pathways Cagrilintide slows gastric transit through amylin and calcitonin receptor activation Combined effects produce more sustained gastric delay than single agents Prolonged nutrient exposure in the small intestine enhances incretin release This dual-pathway gastric slowing mechanism may explain enhanced satiety and reduced caloric intake observed in combination studies
Ozempic persistently accounted for most of the prescriptions, but prescription fills for Wegovy soared by more than 1,361% between July 2021 and December 2023
Be open and honest about any pre-existing conditions and allergies, so we can make sure it's a good fit before beginning treatment
Notably, the lower weight loss (-13.7%) observed in REDEFINE 2 among individuals with T2D suggests that the magnitude of benefit achieved with combined GLP-1 and amylin receptor agonism may depend on the underlying metabolic status, highlighting the need for a more nuanced understanding of the mechanisms governing treatment response [13]